RHYTHM PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$480M
↑+22.4% +$88Mvs FY2024
Total Liabilities
$210M
↓-7.7% -$18Mvs FY2024
Equity
$139M
↑+540.0% +$117Mvs FY2024
Cash
$54M
↓-39.1% -$35Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $480M | $392M |
| Current Assets | $467M | $374M |
| Cash | $54M | $89M |
| ST Investments | $335M | $231M |
| Receivables | $26M | $19M |
| Inventory | $26M | $19M |
| Other Current | $26M | $16M |
| Non-Current Assets | $13M | $18M |
| PPE | $1M | $632K |
| Goodwill | $0 | $0 |
| Intangibles | $5M | $6M |
| Investments | $0 | $0 |
| Other Non-Current | $7M | $11M |
| Total Liab+Eq | $349M | $249M |
| Current Liab. | $106M | $116M |
| Accounts Payable | $14M | $12M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $194K | $1M |
| Other CL | $92M | $102M |
| Non-Current Liab. | $104M | $112M |
| Long-Term Debt | $101M | $108M |
| Other LT Liab. | $3M | $4M |
| Equity | $139M | $22M |
| Retained Earnings | $1.35B | $1.16B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · RYTM · Comparing FY2025 vs FY2024